Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

31 maj 2013 uppdaterad av: National Cancer Institute (NCI)

An Exploratory Study to Evaluate the Effect of HPV 16 Vaccine on the Reduction of Viral Load in HPV 16 Positive Women With Persistent Viral Infection, But Low Grade Disease (ASCUS/LSIL)

This randomized phase II trial is studying how well SGN-00101 vaccine works compared to a placebo in treating human papillomavirus and preventing cervical cancer in patients with abnormal cervical cells. Vaccines, such as SGN-00101, may make the body build an immune response to kill human papillomavirus and abnormal cervical cells and may be effective in preventing cervical cancer

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVES:

I. Compare the effectiveness of SGN-00101 vaccine vs placebo in reducing the human papillomavirus (HPV)-16 viral load in patients with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesions (LSIL) of the cervix with persistent HPV-16 infection who are at increased risk for developing a high-grade squamous intraepithelial lesion or invasive cervical cancer.

II. Compare the natural history of HPV-16 viral load in patients treated with these regimens.

III. Compare the effect of HPV-16 variants on viral load response in patients treated with these regimens.

IV. Compare the relative effectiveness of these regimens on the regression of cervical cellular atypias (based on Pap test results), in terms of the regression of cytologic findings of LSIL and ASCUS to normal findings and resolution or regression of colposcopically defined cervicovaginal lesions, in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive SGN-00101 vaccine subcutaneously (SC) on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.

ARM II: Patients receive placebo vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.

Patients are followed at 12, 24, and 52 weeks after the last vaccination.

Studietyp

Interventionell

Inskrivning (Faktisk)

139

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Orange, California, Förenta staterna, 92868
        • University of California Medical Center At Irvine-Orange Campus

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 50 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Meets criteria for 1 of the following groups:

    • Prospective group, meeting the following criteria:

      • Evidence of atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesions (LSIL) by Pap test
      • Human papillomavirus (HPV)-16-positive by polymerase chain reaction (PCR) and PGMY09/PGMY11 oligonucleotide primers viral load assay
    • Medical records-based group, meeting the following criteria:

      • Medical-record evidence of ASCUS or LSIL by Pap test within the past 6-12 months
      • Meets 1 of the following criteria:

        • Liquid-cytology findings of ASCUS or LSIL
        • Colposcopic evidence of a LSIL by the Reid Index score of 1-5
      • Historically persistent HPV-16-infection by PCR and HPV reverse transcription (RT)-PCR
      • No evidence of high-grade squamous intraepithelial lesions (HSIL) by colposcopy (Reid Index ≥ 6)
      • Reports no sex partner change since last index Pap screening test
    • Specimen-based group, meeting the following criteria:

      • Medical-record evidence of ASCUS or LSIL by Pap test within the past 6-12 months

        • Liquid-based cytology specimen available
      • Meets 1 of the following criteria:

        • Liquid-cytology findings of ASCUS or LSIL
        • Colposcopic evidence of a LSIL by the Reid Index score of 1-5
      • Historically persistent HPV-16-infection by PCR and, where measurable, HPV RT-PCR showing no greater than 3-fold reduction over the index liquid-cytology specimen
      • No evidence of HSIL by colposcopy (Reid Index ≥ 6)
  • Menstrual period occurred at least once within the past 52 weeks
  • No HSIL by Pap test within the past year
  • Performance status - ECOG 0
  • No severe or unstable coagulation
  • Hepatitis B surface antigen negative
  • Hepatitis C antibody negative
  • No angina
  • No heart failure
  • No other cardiac condition
  • No respiratory condition
  • No asthma
  • No immunological disorders (e.g., lupus, diabetes, multiple sclerosis, or myasthenia gravis)
  • Not immunocompromised, suggestive of severe immune deficiency
  • HIV negative
  • No AIDS
  • No active infection, defined as fever > 100° F
  • No syphilis
  • No severe allergic reactions (anaphylactic response) to drugs or any other allergen
  • No history of allergy to any vaccine constituents, including cell- or tissue-system elements used to prepare the vaccine (e.g., bread products, yeast, or recombinant DNA technology using yeast systems)
  • Must agree to use effective form of contraception throughout vaccination period
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during vaccination period and for 5 months after study treatment
  • No sexual intercourse within 48 hours of virus specimen collection during study visits
  • No objects (e.g., tampons, douche, suppositories, fingers, or toes) within the vagina or rectum within 48 hours of virus specimen collection during study visits
  • No prior malignancy except nonmelanoma skin cancer
  • No medical or psychiatric illness than would preclude study participation or compliance
  • No other disorders requiring medical intervention that would preclude study participation
  • No prior HPV vaccine
  • More than 30 days since prior investigational vaccine
  • More than 30 days since prior systemic steroid therapy
  • No prior splenectomy
  • More than 30 days since prior investigational drug
  • More than 72 hours since prior antibiotic therapy for active infection

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm I (SGN-00101)
Patients receive SGN-00101 vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
Korrelativa studier
Given SC
Andra namn:
  • HPV 16 E7/HSP65-vaccin
  • HPV E7 peptidepitopvaccin
  • SGN-00101
Placebo-jämförare: Arm II (placebo)
Patients receive placebo vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
Korrelativa studier
Given SC
Andra namn:
  • PLCB

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
HPV-16 viral load
Tidsram: 6 months
Following the univariate modeling, multivariate logistic regression models will be constructed by adding the demographic factors, baseline viral load, and type of cellular atypia to the model. The univariate logistic regression model for infection resolution is equivalent to a chi-square test.
6 months
Natural history of HPV 16 viral load
Tidsram: Baseline
A repeated measures version of the zero-inflated log-normal model will be constructed.
Baseline
Natural history of HPV 16 viral load
Tidsram: 3 months
A repeated measures version of the zero-inflated log-normal model will be constructed.
3 months
Natural history of HPV 16 viral load
Tidsram: 6 months
A repeated measures version of the zero-inflated log-normal model will be constructed.
6 months
Regression or non-regression of the cellular atypia
Tidsram: Up to 52 weeks
The analysis for this will employ logistic regression models. A multivariate logistic regression model will be constructed. . A two group continuity corrected chi squared test with a 0.050 two-sided significance level will be used.
Up to 52 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
HPV-16 viral load
Tidsram: 3 months
Following the univariate modeling, multivariate logistic regression models will be constructed by adding the demographic factors, baseline viral load, and type of cellular atypia to the model. The univariate logistic regression model for infection resolution is equivalent to a chi-square test.
3 months
Time to infection resolution
Tidsram: Up to 52 weeks
Kaplan Meier curves will be constructed.
Up to 52 weeks
Time to disease resolution
Tidsram: Up to 52 weeks
Kaplan Meier curves will be constructed.
Up to 52 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Frank Meyskens, University of California Medical Center At Irvine-Orange Campus

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 september 2004

Primärt slutförande (Faktisk)

1 juni 2007

Studieregistreringsdatum

Först inskickad

7 september 2004

Först inskickad som uppfyllde QC-kriterierna

7 september 2004

Första postat (Uppskatta)

8 september 2004

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

3 juni 2013

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

31 maj 2013

Senast verifierad

1 mars 2013

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • NCI-2012-02623
  • UCI#02-55
  • N01CN25139 (Annat bidrag/finansieringsnummer: US NIH Grant/Contract Award Number)
  • CDR0000383786 (Registeridentifierare: PDQ (Physician Data Query))

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Livmoderhalscancer

Kliniska prövningar på laboratoriebiomarköranalys

3
Prenumerera